CLICK HERE FOR BRIUMVI® (ublituximab-xiiy) PRESCRIBING INFORMATION

FIERCELY FOCUSED
ON OUTCOMES

CLINICAL TRIAL INFORMATION AND RECRUITMENT

TG Therapeutics is committed to the development of innovative medicines and unique combinations that deliver novel treatments for patients suffering from B-cell malignancies and autoimmune diseases. An integral part of achieving this goal is the conduct of robust and efficient clinical trials at the highest standards of quality attainable.

Information on all of TG Therapeutics’ ongoing clinical trials, including information for healthcare providers and patients interested in participating in any ongoing clinical trials, can be found at www.ClinicalTrials.gov,

Our REGISTRATION-DIRECTED AND PIVOTAL PHASE 3 TRIALS

PHASE 2b UNITY-NHL TRIAL

ONGOING, BUT NO LONGER RECRUITING

PHASE 2 ULTRA-V TRIAL

ONGOING, BUT NO LONGER RECRUITING

PHASE 3 ULTIMATE I & II TRIALS

ONGOING, BUT NO LONGER RECRUITING

UNITY-CLL PHASE 3 TRIAL

ONGOING, BUT NO LONGER RECRUITING